Bioavailability of ifosfamide in patients with bronchial carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108033
Title:
Bioavailability of ifosfamide in patients with bronchial carcinoma.
Authors:
Cerny, T; Margison, Jennifer M; Thatcher, Nick; Wilkinson, Peter M
Abstract:
The pharmacokinetics of ifosfamide (I) were determined in ten patients with bronchogenic carcinoma. In seven patients, doses of 1 and 2 g (I) were given both as a bolus orally and later intravenously and were well tolerated. A further three patients received 5 g (I) as a single oral dose but in two this produced reversible CNS toxicity and severe vomiting. The area under the curve (AUC, microgram . h . l-1) for the 1-g dose was the same following oral and i.v. treatment and this was also true for the 2-g doses. There was a proportionate increase in the AUC for the 5-g oral dose, indicating 100% bioavailability at all three dose levels. We conclude that doses up to 2 g by mouth represent a well-tolerated alternative route of administration.
Affiliation:
Department of Medical Oncology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, UK.
Citation:
Bioavailability of ifosfamide in patients with bronchial carcinoma. 1986, 18 (3):261-4 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1986
URI:
http://hdl.handle.net/10541/108033
DOI:
10.1007/BF00273399
PubMed ID:
3802382
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorCerny, Ten
dc.contributor.authorMargison, Jennifer Men
dc.contributor.authorThatcher, Nicken
dc.contributor.authorWilkinson, Peter Men
dc.date.accessioned2010-07-21T10:21:55Z-
dc.date.available2010-07-21T10:21:55Z-
dc.date.issued1986-
dc.identifier.citationBioavailability of ifosfamide in patients with bronchial carcinoma. 1986, 18 (3):261-4 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid3802382-
dc.identifier.doi10.1007/BF00273399-
dc.identifier.urihttp://hdl.handle.net/10541/108033-
dc.description.abstractThe pharmacokinetics of ifosfamide (I) were determined in ten patients with bronchogenic carcinoma. In seven patients, doses of 1 and 2 g (I) were given both as a bolus orally and later intravenously and were well tolerated. A further three patients received 5 g (I) as a single oral dose but in two this produced reversible CNS toxicity and severe vomiting. The area under the curve (AUC, microgram . h . l-1) for the 1-g dose was the same following oral and i.v. treatment and this was also true for the 2-g doses. There was a proportionate increase in the AUC for the 5-g oral dose, indicating 100% bioavailability at all three dose levels. We conclude that doses up to 2 g by mouth represent a well-tolerated alternative route of administration.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdministration, Oral-
dc.subject.meshAged-
dc.subject.meshBiological Availability-
dc.subject.meshCarcinoma, Bronchogenic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshKinetics-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.titleBioavailability of ifosfamide in patients with bronchial carcinoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, M20 9BX Manchester, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.